MAT (Medication-Assisted Treatment)

MAT for opioid use disorder (MOUD)

Three FDA-approved medications, each targeting opioid receptors differently:

MAT for alcohol use disorder

Three FDA-approved medications for alcohol use disorder, all underutilized — only ~7% of patients with AUD receive any pharmacotherapy:

• Naltrexone (oral or Vivitrol) — reduces craving and reward; first-line per VA/DoD guideline.
• Acamprosate (Campral) — modulates glutamate; helps maintain abstinence after detox; safe in liver disease.
• Disulfiram (Antabuse) — produces severe physical reaction if alcohol consumed; effective when supervised, less so when self-administered.

Topiramate and gabapentin are commonly used off-label and have evidence (especially for craving and sleep), though not FDA-approved for AUD.

The 2023 X-waiver removal

Until December 2022, prescribing buprenorphine required a special "X-waiver" from DEA — an 8-hour training plus a separate registration. The Mainstreaming Addiction Treatment (MAT) Act, signed into law December 2022 and effective 2023, removed this barrier. Any DEA-registered clinician can now prescribe buprenorphine. This change is the most important opioid-policy shift since the Drug Addiction Treatment Act of 2000 — it's expected to roughly triple the number of buprenorphine prescribers over a decade.

MAT in practice — what an induction visit looks like

The single most-misunderstood part of MAT is the induction visit — the first dose. Patients arrive worried it will hurt, that they'll be judged, or that something dramatic will happen. The reality is much less dramatic, and understanding it removes the main barrier to starting.

Buprenorphine induction

Standard protocol: patient arrives in mild-to-moderate withdrawal (12–18 hours after last short-acting opioid, 24–48 hours after long-acting like methadone). Clinician confirms withdrawal severity using COWS (Clinical Opioid Withdrawal Scale). Score above 8 confirms readiness. Clinician administers initial 4 mg sublingual buprenorphine, observes for 60–90 minutes. If improvement, gives a second 4 mg dose. Total day-one dose typically 8–12 mg. Patient leaves with a 7–14 day prescription, returns in a week for follow-up. Most patients describe the relief of withdrawal disappearing as "the most relief I've felt in years."

Methadone induction

Restricted to federally certified Opioid Treatment Programs (OTPs) — patient arrives at the OTP daily for the first 14–30 days. Initial dose is conservative (10–30 mg) and titrates up by 5–10 mg every 1–2 days based on response. By week 4, most patients are on a stable dose (typically 60–120 mg/day). Take-home doses are earned with stability — initially weekend only, then progressively more.

Naltrexone induction

Different mechanism = different protocol. Naltrexone is an antagonist — it BLOCKS opioid receptors. If a patient has any opioid in their system, naltrexone precipitates immediate severe withdrawal. So the protocol requires 7–10 days fully opioid-free before induction. This is the main barrier to naltrexone use — many patients can't manage 7+ days without using. Some programs use brief inpatient detox to bridge to extended-release naltrexone (Vivitrol) injection on discharge day.

Common patient questions about MAT

• "Will I get high?" No. At therapeutic maintenance doses, buprenorphine and methadone do not produce euphoria. Patients describe feeling "normal" or "neutral" — the absence of withdrawal craving rather than positive effect.
• "How long do I have to take it?" No fixed timeline. Per current evidence (Sordo 2017 BMJ meta-analysis), longer maintenance correlates with lower mortality. Many clinicians advise: stay on it as long as it's working, taper only when life is otherwise stable. Some patients stay on for years; some taper after 12–18 months. Both are valid paths.
• "Will my employer drug-test me?" Buprenorphine doesn't show on standard 5-panel drug tests (it requires a specific test). Methadone DOES show on standard tests but is documented in your medication record — providing an Rx letter to a drug-testing program is standard practice and accepted by most employers under ADA.
• "What happens if I miss a dose?" Buprenorphine: skip the missed dose, take the next as scheduled. Don't double up. Methadone: similar guidance, but consult OTP. Withdrawal returns within 24–36 hours of a missed buprenorphine dose, so don't go more than 1 day without contacting your prescriber.
• "Can I drink while on MAT?" Buprenorphine + heavy alcohol = increased respiratory depression risk. Light social drinking may be acceptable for some patients but discuss with prescriber. Methadone + alcohol same concern. Naltrexone interacts differently — if you're on naltrexone for alcohol use disorder, drinking is the entire reason you're taking it.
• "What if I want to stop the medication?" Talk to your prescriber FIRST. Don't taper alone. Premature taper is associated with relapse and overdose because tolerance has dropped. A supervised taper over weeks or months — with backup plans for relapse signals — is the standard.

FDA safety warnings — what every MAT patient should know

All four FDA-approved opioid- and alcohol-MAT medications carry safety warnings that prescribers are required to discuss at induction. They are not reasons to avoid MAT — the benefits substantially outweigh these risks for properly screened patients — but understanding them is part of informed consent.

MAT and pregnancy

Both buprenorphine and methadone are recommended in pregnancy for opioid use disorder per ACOG, AAP, and SAMHSA. The alternatives — abstinence-based detox during pregnancy or continued unmanaged opioid use — both have substantially worse outcomes for mother and infant. Newborns of mothers on MAT can develop neonatal abstinence syndrome (NAS), which is treatable in the NICU and not associated with long-term developmental harm when properly managed. The benefits of stable maternal opioid agonist treatment vastly outweigh the risk of NAS. ACOG Committee Opinion 711 is the current standard.

Frequently Asked Questions